Coronavirus in Kyrgyzstan
World|science|August 19, 2020 / 03:21 PM
Scientists in Israel develop COVID-19 testing with 95% accuracy rate

AKIPRESS.COM - Israeli scientists will launch clinical trials for new coronavirus test with a 95% accuracy rate, ISRAEL21c reports.

Results of a COVID-19 test are available in less than a minute, from a single sample of saliva, according to the media.

“Under laboratory conditions, we were clearly able to differentiate between COVID-19 samples that were positive and those that were negative, with a 95% accuracy rate,” said trial leader Dr. Eli Schwartz, founder of Sheba’s Center for Geographic Medicine and Tropical Diseases.

Newsight’s core business is advanced image sensor chips for 3D machine vision and spectral analysis, used in verticals such as mobile, robotics, Industry 4.0, automotive safety and surveillance.

“With our team of experts in chip design, optics and microbiology, in a great collaboration with Prof. Schwartz and his team, we were able to utilize our groundbreaking advantages in the machine vision world, validated in our 3D technology, into the spectral analysis world, and specifically to virus detection,” he said.

This AI based solution is unique as scientists have developed technology solution starting from a spectral chip, through its firmware, boards and AI algorithms, researcher noted.

The company has already sold a license to develop virus and bacteria detection devices based on its technology, to Hong Kong company AIinnoBio.

The Israeli clinical trial will test Newsight’s SpectraLit on hundreds more patients for another four to six weeks, after which final results will be analyzed.

All rights reserved

© AKIpress News Agency - 2001-2020.

Republication of any material is prohibited without a written agreement with AKIpress News Agency.

Any citation must be accompanied by a hyperlink to akipress.com.

Our address:

189 Moskovskaya st., Bishkek, the Kyrgyz Republic

e-mail: english@akipress.org, akipressenglish@gmail.com;

Tel/Fax: +996(312)65-03-06

Follow us: